MedPath

A trial to compare conventional drug therapy versus conventional drug therapy along with Pulmonary Rehabilitation in patients with Interstitial Lung Disease.

Not Applicable
Conditions
Health Condition 1: J848- Other specified interstitial pulmonary diseases
Registration Number
CTRI/2022/11/047192
Lead Sponsor
JIPMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Age above 18 years

ILD of any types (Idiopathic Interstitial Pneumonia, Autoimmune ILD, Sarcoidosis, other ILDs)

Exclusion Criteria

1. Other conditions which are contraindications for spirometry, according to American Thoracic Society guidelines.

2.Thoracic surgery in the previous six months or Patient with previous hospitalization in the last 3 weeks.

2. Patient not willing to do PR

3.Orthopaedic conditions which interfere with walking

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the effect of conventional drug therapy along with a home-based, 12 -week pulmonary rehabilitation program on 6MWT performance capacity of ILD patients when compared to conventional drug therapy alone.Timepoint: 12 weeks
Secondary Outcome Measures
NameTimeMethod
To study the effect of home-based, Pulmonary Rehabilitation on <br/ ><br>â?¢Pulmonary function, assessed by Spirometry <br/ ><br>â?¢Breathlessness, assessed by mMRC Dyspnoea Scale <br/ ><br>â?¢Respiratory function, assessed by St George Respiratory Questionnaire <br/ ><br>Timepoint: 12 weeks
© Copyright 2025. All Rights Reserved by MedPath